{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:16:35Z","timestamp":1793132195716,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stockholm Regional Council","award":["FoUI-949280"],"award-info":[{"award-number":["FoUI-949280"]}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2011-02497"],"award-info":[{"award-number":["2011-02497"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2011-02497"],"award-info":[{"award-number":["2011-02497"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Royal Institute of Technology","award":["Faculty Grant"],"award-info":[{"award-number":["Faculty Grant"]}]},{"name":"HelseNord","award":["HNF1544-20"],"award-info":[{"award-number":["HNF1544-20"]}]},{"DOI":"10.13039\/501100009764","name":"Landstinget Blekinge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009764","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ingemanssonska Foundation"},{"name":"The Operational Healthcare Committee, Region V\u00e4stra G\u00f6taland"},{"DOI":"10.13039\/501100004270","name":"Royal Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic low-grade inflammation is a well-known risk factor for coronary heart disease (CHD) and future cardiovascular events. Anti-inflammatory therapy can reduce the risk of ischemic cardiovascular disease (CVD) events following myocardial infarction (MI). However, it remains unknown to what extent inflammation at the time of an acute event predicts long-term outcomes. We explored whether routine blood measurements of inflammatory markers during an acute coronary syndrome (ACS) are predictive of long-term mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a cohort of 5292 consecutive patients admitted to a coronary intensive care unit with suspected ACS over a four-year period in the Carlscrona Heart Attack Prognosis Study (CHAPS), 908 patients aged 30\u201374\u00a0years (644 men, 264 women) were diagnosed with MI (527) or unstable angina (UA) (381). A 10-year follow-up study was conducted using Swedish national registries, with total mortality and cardiac mortality as primary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Long-term total and cardiac mortality were significantly associated with higher leukocyte counts (e.g., neutrophils, monocytes, p\u2009\u2264\u20090.001), higher levels of inflammatory biomarkers (e.g., C-reactive protein, Serum Amyloid A, fibrinogen, p\u2009\u2264\u20090.001), and elevated neutrophil\u2013lymphocyte ratio (NLR) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and monocyte-lymphocyte ratio (MLR) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), all measured at ACS admission. These associations were independent of ACS diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that level of inflammation at ACS presentation\u2014beyond its established role as a major CHD risk factor\u2014also predicts long-term mortality following ACS. Notably, inflammation at the time of the event was a stronger predictor of long-term mortality than the acute event outcome itself. However, limitations include the observational study design, moderate sample size, and absence of modern high-sensitivity cardiac biomarkers and contemporary ACS management strategies in this cohort. The results should therefore be interpreted in the context of historical clinical practice. While our model-wise complete-case approach ensured consistency, missing data remains a potential source of bias. Future studies in larger, more contemporary cohorts are needed to validate these findings and refine risk stratification strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-04608-9","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T05:34:58Z","timestamp":1742016898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Markers of inflammation predicts long-term mortality in patients with acute coronary syndrome \u2013 a cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jacob","family":"Odeberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Halling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ringborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar","family":"Vaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"R\u00e5stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Odeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Lindblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"1","key":"4608_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","volume":"124","author":"P Libby","year":"2019","unstructured":"Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the Mechanisms of Acute Coronary Syndromes. Circ Res. 2019;124(1):150\u201360.","journal-title":"Circ Res"},{"issue":"1","key":"4608_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archinte.160.1.25","volume":"160","author":"JA Ambrose","year":"2000","unstructured":"Ambrose JA, Dangas G. Unstable angina: current concepts of pathogenesis and treatment. Arch Intern Med. 2000;160(1):25\u201337.","journal-title":"Arch Intern Med"},{"issue":"10","key":"4608_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.4065\/84.10.917","volume":"84","author":"A Kumar","year":"2009","unstructured":"Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917\u201338.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"4608_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrcardio.2016.166","volume":"14","author":"G Pasterkamp","year":"2017","unstructured":"Pasterkamp G, den Ruijter HM, Libby P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat Rev Cardiol. 2017;14(1):21\u20139.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"4608_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1373\/clinchem.2007.097360","volume":"54","author":"RR Packard","year":"2008","unstructured":"Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24\u201338.","journal-title":"Clin Chem"},{"issue":"1","key":"4608_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009968","volume":"6","author":"J Odeberg","year":"2016","unstructured":"Odeberg J, Freitag M, Forssell H, Vaara I, Persson ML, Odeberg H, et al. Influence of pre-existing inflammation on the outcome of acute coronary syndrome: a cross-sectional study. BMJ Open. 2016;6(1): e009968.","journal-title":"BMJ Open"},{"issue":"4","key":"4608_CR7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/ATVBAHA.118.310958","volume":"39","author":"P Libby","year":"2019","unstructured":"Libby P, Everett BM. Novel Antiatherosclerotic Therapies. Arterioscler Thromb Vasc Biol. 2019;39(4):538\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"26","key":"4608_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497\u2013505.","journal-title":"N Engl J Med"},{"issue":"12","key":"4608_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"4608_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005077","volume":"4","author":"J Odeberg","year":"2014","unstructured":"Odeberg J, Freitag M, Forssell H, Vaara I, Persson ML, Odeberg H, et al. The influence of smoking and impaired glucose homoeostasis on the outcome in patients presenting with an acute coronary syndrome: a cross-sectional study. BMJ Open. 2014;4(7): e005077.","journal-title":"BMJ Open"},{"issue":"20","key":"4608_CR11","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1161\/01.CIR.0000100560.46946.EA","volume":"108","author":"RV Luepker","year":"2003","unstructured":"Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108(20):2543\u20139.","journal-title":"Circulation"},{"issue":"21","key":"4608_CR12","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"4","key":"4608_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/j.1538-7836.2006.01835.x","volume":"4","author":"J Odeberg","year":"2006","unstructured":"Odeberg J, Freitag M, Odeberg H, Rastam L, Lindblad U. Severity of acute coronary syndrome is predicted by interactions between fibrinogen concentrations and polymorphisms in the GPIIIa and FXIII genes. J Thromb Haemost. 2006;4(4):909\u201312.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"4608_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","volume":"55","author":"RJ Glynn","year":"2009","unstructured":"Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem. 2009;55(2):305\u201312.","journal-title":"Clin Chem"},{"issue":"10118","key":"4608_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319\u201328.","journal-title":"Lancet"},{"issue":"38","key":"4608_CR16","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499\u2013507.","journal-title":"Eur Heart J"},{"issue":"25","key":"4608_CR17","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","volume":"72","author":"PM Ridker","year":"2018","unstructured":"Ridker PM. Clinician\u2019s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J Am Coll Cardiol. 2018;72(25):3320\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"4608_CR18","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","volume":"70","author":"P Libby","year":"2017","unstructured":"Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70(18):2278\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"4608_CR19","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","volume":"41","author":"N Bouabdallaoui","year":"2020","unstructured":"Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41(42):4092\u20139.","journal-title":"Eur Heart J"},{"issue":"26","key":"4608_CR20","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMe1914378","volume":"381","author":"LK Newby","year":"2019","unstructured":"Newby LK. Inflammation as a Treatment Target after Acute Myocardial Infarction. N Engl J Med. 2019;381(26):2562\u20133.","journal-title":"N Engl J Med"},{"issue":"10","key":"4608_CR21","doi-asserted-by":"publisher","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","volume":"6","author":"C Held","year":"2017","unstructured":"Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, et al. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077.","journal-title":"J Am Heart Assoc."},{"issue":"19","key":"4608_CR22","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","volume":"163","author":"CB Granger","year":"2003","unstructured":"Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345\u201353.","journal-title":"Arch Intern Med"},{"issue":"7","key":"4608_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jama.284.7.835","volume":"284","author":"EM Antman","year":"2000","unstructured":"Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina\/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835\u201342.","journal-title":"JAMA"},{"issue":"43","key":"4608_CR24","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1093\/eurheartj\/ehae593","volume":"45","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zeller M, Auffret V, Georgiopoulos G, Raber L, Roffi M, et al. Sex-specific prediction of cardiogenic shock after acute coronary syndromes: the SEX-SHOCK score. Eur Heart J. 2024;45(43):4564\u201378.","journal-title":"Eur Heart J"},{"issue":"1","key":"4608_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12872-021-02311-z","volume":"22","author":"L Yanqiao","year":"2022","unstructured":"Yanqiao L, Shen L, Yutong M, Linghong S, Ben H. Comparison of GRACE and TIMI risk scores in the prediction of in-hospital and long-term outcomes among East Asian non-ST-elevation myocardial infarction patients. BMC Cardiovasc Disord. 2022;22(1):4.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4\u20135","key":"4608_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clinbiochem.2013.12.014","volume":"47","author":"AP Doumatey","year":"2014","unstructured":"Doumatey AP, Zhou J, Adeyemo A, Rotimi C. High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-term archived human serum. Clin Biochem. 2014;47(4\u20135):315\u20138.","journal-title":"Clin Biochem"},{"key":"4608_CR27","doi-asserted-by":"crossref","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer Nature : Springer; 2019.","DOI":"10.1007\/978-3-030-16399-0"},{"issue":"4","key":"4608_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","volume":"55","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2020;55(4):675\u201380.","journal-title":"Bone Marrow Transplant"},{"key":"4608_CR29","doi-asserted-by":"crossref","unstructured":"Harrell FE, SpringerLink. Regression modeling strategies : with applications to linear models, logistic and ordinal regression, and survival analysis. Second edition ed. Cham: Springer International Publishing : Imprint: Springer; 2015.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"4608_CR30","doi-asserted-by":"publisher","unstructured":"Little RJA, Rubin DB. Statistical analysis with missing data. 3rd ed. Hoboken: Wiley; 2020. https:\/\/doi.org\/10.1002\/9781119013563.","DOI":"10.1002\/9781119013563"},{"key":"4608_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338: b2393.","journal-title":"BMJ"},{"issue":"3","key":"4608_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237\u201369.","journal-title":"Eur Heart J"},{"issue":"9","key":"4608_CR33","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013119.","journal-title":"Circulation"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04608-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T05:35:19Z","timestamp":1742016919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04608-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4608"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04608-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4973727\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carlscrona Heart Attack Prognosis Study (CHAPS) was approved by the Regional Ethical Review Board, Lund, Sweden (EPN 2009\/762 and LU 298\u201391). All participants gave their informed consent before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}